ArticleKorean journal of ophthalmology : KJO2014
Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab.
Article in Korean journal of ophthalmology : KJO, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02695641 (A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections: a systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Pooled it
- Pooled it
- An assessment of anti-VEGF drugs safety based on real-world data: from popularity to spontaneous reporting in eudravigilance database.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab.Ophthalmology and therapy · 2025Article
- Simultaneous bilateral intravitreal anti-vascular endothelial growth factor injections from one vial for diabetic macular edema: a retrospective analysis.Frontiers in medicine · 2025Article
- Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents.Clinical ophthalmology (Auckland, N.Z.) · 2017Article
- Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy.Investigational new drugs · 2016Article
- Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Clinical interventions in aging · 2016Article
- Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors.International journal of ophthalmology · 2014Article
- Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study compared serum vascular endothelial growth factor (VEGF) concentration between patients given the bilateral and unilateral intravitreal injections of bevacizumab.
methodsIn a prospective manner, serum VEGF levels in treatment-naive patients with age-related macular degeneration who underwent bilateral or unilateral intravitreal injections of bevacizumab were investigated. After informed consent, peripheral blood was collected from in patients who underwent bilateral or unilateral intravitreal injection of bevacizumab before and 1 month after the injection. Serum VEGF levels were measured by enzyme-linked immunosorbent assay after centrifugation. In addition, best-corrected visual acuity (BCVA) and central retinal thickness (CRT) before and 1 month after the injection were compared between each group.
resultsTwenty patients received bilateral injections (40 eyes) and 20 patients received unilateral injections. The VEGF concentrations (pg/mL) before the bilateral injection were 235.75 ± 183.16 and 252.53 ± 233.52 for the unilateral injection. They were significantly reduced to 153.88 ± 113.26 and 189.42 ± 251.72 after 1 month, respectively (p = 0.037 and 0.019), which are showing no significant difference between the two groups (p = 0.771). And there were no significant intergroup difference in pre- and postoperative BCVA and CRT.
conclusionsThe bilateral simultaneous intravitreal injection of bevacizumab did not differ greatly from unilateral intravitreal injection in the influence on serum VEGF levels and the therapeutic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.